Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2021 - 2025)
Kiniksa Pharmaceuticals International's Enterprise Value history spans 5 years, with the latest figure at -$414.1 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 69.96% year-over-year to -$414.1 million; the TTM value through Dec 2025 reached -$414.1 million, down 69.96%, while the annual FY2025 figure was -$414.1 million, 69.96% down from the prior year.
- Enterprise Value reached -$414.1 million in Q4 2025 per KNSA's latest filing, up from -$529.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$145.6 million in Q1 2022 to a low of -$529.3 million in Q3 2025.
- Average Enterprise Value over 5 years is -$249.5 million, with a median of -$216.2 million recorded in 2024.
- Peak YoY movement for Enterprise Value: surged 44.91% in 2022, then plummeted 74.15% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$182.2 million in 2021, then fell by 4.61% to -$190.6 million in 2022, then dropped by 8.27% to -$206.4 million in 2023, then decreased by 18.05% to -$243.6 million in 2024, then crashed by 69.96% to -$414.1 million in 2025.
- Per Business Quant, the three most recent readings for KNSA's Enterprise Value are -$414.1 million (Q4 2025), -$529.3 million (Q3 2025), and -$307.8 million (Q2 2025).